Scarica l'app Stockscreener
43.80
3.12%
-1.41
Dopo l'orario di chiusura:
43.80
Precedente Chiudi:
$45.21
Aprire:
$44.25
Volume 24 ore:
1.75M
Relative Volume:
3.43
Capitalizzazione di mercato:
$1.21B
Reddito:
$17.16M
Utile/perdita netta:
$-163.62M
Rapporto P/E:
-7.2039
EPS:
-6.08
Flusso di cassa netto:
$-121.61M
1 W Prestazione:
-9.65%
1M Prestazione:
-1.60%
6M Prestazione:
+80.62%
1 anno Prestazione:
+205.01%
Intervallo 1D:
$43.49
$45.02
Intervallo di 1 settimana:
$42.00
$48.57
Portata 52W:
$12.21
$52.47
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Confronta ANAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
43.80 | 1.25B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
Anaptysbio CFO Mulroy sells $86k in shares By Investing.com - Investing.com Canada
Anaptysbio chief legal officer Loumeau sells $439k in stock - Investing.com
AnaptysBio CMO Lizzul sells $100k in stock - Investing.com
What dividend safety score for AnaptysBio Inc. stockWeekly Profit Summary & Long-Term Capital Growth Ideas - ulpravda.ru
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty - Reuters
AnaptysBio files motion to dismiss in Tesaro/GSK royalty dispute - Investing.com
AnaptysBio, Inc. Files Motion to Dismiss Breach of Contract Claim Amid Ongoing Dispute with Tesaro and GSK, Trial Set for July 2026 - Quiver Quantitative
Anaptys Files Motion to Dismiss Tesaro’s Claim of - GlobeNewswire
AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 9,639 Shares - MarketBeat
Insider Selling: AnaptysBio (NASDAQ:ANAB) CEO Sells $415,102.22 in Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Sells $100,820.85 in Stock - MarketBeat
Why analysts upgrade AnaptysBio Inc. stockEarnings Growth Summary & Weekly High Conviction Trade Ideas - ulpravda.ru
Will AnaptysBio Inc. stock reach Wall Street targets2025 Market Sentiment & Accurate Intraday Trade Tips - ulpravda.ru
Can AnaptysBio Inc. stock sustain market leadershipRecession Risk & Daily Technical Forecast Reports - ulpravda.ru
UBS Raises AnaptysBio (ANAB) Price Target to $70, Upgrades to Buy | ANAB Stock News - GuruFocus
AnaptysBio (NASDAQ:ANAB) Shares Gap UpHere's Why - MarketBeat
AnaptysBio stock rating initiated at Buy by UBS with $70 price target - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Insider Paul Lizzul Sells 4,219 Shares - MarketBeat
Anaptysbio CLO Eric Loumeau sells $129k in shares By Investing.com - Investing.com Canada
Anaptysbio CFO Mulroy sells $145k in shares By Investing.com - Investing.com Canada
Anaptysbio CEO Faga sells $662k in shares - Investing.com
Insider Selling: AnaptysBio (NASDAQ:ANAB) Insider Sells 2,983 Shares of Stock - MarketBeat
Anaptysbio CLO Eric Loumeau sells $129k in shares - Investing.com
AnaptysBio, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - Quiver Quantitative
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
AnaptysBio, Inc. $ANAB Shares Sold by Voya Investment Management LLC - MarketBeat
Is AnaptysBio Inc AN6 a good long term investmentTrading Volume Surges & High Profit Investment Ideas - earlytimes.in
New Highs: Is AnaptysBio Inc stock a safe haven assetEarnings Growth Report & AI Forecasted Stock Moves - moha.gov.vn
Anaptysbio CEO Faga sells $662k in shares By Investing.com - Investing.com Canada
This biotech stock has more than tripled in 2025, but red flags are waving - MSN
AnaptysBio (NASDAQ:ANAB) Stock Price Down 4%Should You Sell? - MarketBeat
Trade Alert: Independent Director Of AnaptysBio J. Ware Has Sold Stock - simplywall.st
AnaptysBio (NASDAQ:ANAB) Hits New 12-Month HighTime to Buy? - MarketBeat
AnaptysBio stock hits 52-week high at $51.58 - Investing.com
AnaptysBio stock hits 52-week high at $51.58 By Investing.com - Investing.com South Africa
Insider Selling: AnaptysBio (NASDAQ:ANAB) Director Sells 3,900 Shares of Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Sells $75,000.00 in Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) CFO Dennis Mulroy Sells 10,000 Shares - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 10,000 Shares - MarketBeat
Anaptysbio Insider Sold Shares Worth $510,000, According to a Recent SEC Filing - marketscreener.com
Anaptysbio Insider Sold Shares Worth $500,000, According to a Recent SEC Filing - marketscreener.com
AnaptysBio Executives and Director Execute Stock Sales - TradingView — Track All Markets
AnaptysBio Executives Sell Shares - TradingView — Track All Markets
AnaptysBio (NASDAQ: ANAB) CMO reports option exercise and stock sale - Stock Titan
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is AnaptysBio Inc. stock a buy in volatile marketsDip Buying & AI Enhanced Market Trend Forecasts - Улправда
AnaptysBio sets $100M stock repurchase plan - MSN
How AnaptysBio Inc. (AN6) stock trades under stagflationJuly 2025 Spike Watch & Smart Allocation Stock Reports - Улправда
This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving - Yahoo Finance
Is AnaptysBio Inc. stock recession proofIPO Watch & Capital Efficiency Focused Strategies - DonanımHaber
AnaptysBio, Inc. $ANAB Shares Bought by Assenagon Asset Management S.A. - MarketBeat
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):